Can Prasugrel Be Discontinued After 4 Years?
Yes, prasugrel can be discontinued after 4 years of therapy following your stent procedures, and you should continue aspirin monotherapy indefinitely. At this point, you have far exceeded the guideline-recommended duration of dual antiplatelet therapy (DAPT).
Guideline-Recommended Duration
The standard duration of DAPT after stent placement is well-established:
- For ACS patients (which includes in-stent restenosis): P2Y12 inhibitor therapy (including prasugrel) should be given for at least 12 months 1, 2, 3
- Beyond 12 months: Continuation may be considered but is optional (Class IIb recommendation) 2, 4, 3
The 2017 ESC guidelines specifically state that DAPT duration decisions should be dynamic and reassessed during treatment, with consideration for discontinuation after 6 months in patients with high bleeding risk 1.
Why 4 Years Exceeds Recommendations
Your 4-year duration of prasugrel therapy is more than 3 times longer than the minimum recommended duration. The evidence supporting extended DAPT beyond 12 months comes primarily from studies examining 30-month therapy, not indefinite continuation 5, 6. Even in these extended duration studies:
- The DAPT study showed that while 30 months reduced stent thrombosis and MI compared to 12 months, it increased bleeding risk and showed a trend toward increased mortality 5
- Benefits must be weighed against bleeding risks, which accumulate over time
Transition Strategy
Discontinue prasugrel and continue aspirin 81 mg daily indefinitely 1, 2, 4:
- Aspirin should be continued lifelong after any coronary stent procedure 2, 4, 3
- The recommended aspirin dose is 75-100 mg (typically 81 mg in the US) 1, 2
- No tapering of prasugrel is required; it can be stopped abruptly
Important Caveats
Monitor for symptoms after discontinuation: There is evidence that MI rates can increase within 90 days after stopping P2Y12 inhibitors, even after extended therapy 5, 6. Watch for:
- New or worsening chest pain
- Shortness of breath
- Any symptoms suggesting cardiac ischemia
Consider bleeding risk factors you may have: The FDA label warns that prasugrel carries significant bleeding risk, particularly with prolonged use 7. Continuing beyond 4 years only increases cumulative bleeding exposure without established benefit.
Ensure no recent ACS events: If you've had any acute coronary events in the past 12 months, discuss timing with your cardiologist, as this would restart the DAPT clock.
Bottom Line
After 4 years of prasugrel following your stent procedures, you have completed more than adequate DAPT duration. Discontinue prasugrel and maintain aspirin 81 mg daily indefinitely. The risk-benefit ratio at this point favors stopping the P2Y12 inhibitor, as bleeding risks accumulate while incremental anti-ischemic benefits beyond 12-30 months are not established.